Anti-hypertrophy effect of atorvastatin on myocardium depends on AMPK activation-induced miR-143-3p suppression via Foxo1 (vol 106, pg 1390, 2018)

被引：0

作者：

Yu, Bo ^{[1
]}

Liu, Dongna ^{[1
]}

Zhang, Hongli ^{[1
]}

Xie, Di ^{[1
]}

Nie, Wei ^{[1
]}

Shi, Kaiyao ^{[1
,2
]}

Yang, Ping ^{[1
,2
]}

机构：

[1] Jilin Univ, Dept Cardiol, Jilin Prov Key Lab Genet Diag Cardiovasc Dis, China Japan Union Hosp, Changchun 130033, Peoples R China

[2] Jilin Univ, Dept Cardiol, Jilin Prov Key Lab Genet Diag Cardiovasc Dis, China Japan Union Hosp, 126 Xiantai Ave, Changchun 130033, Peoples R China

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2024年 / 171卷

关键词：

D O I：

10.1016/j.biopha.2024.116141

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

页数：2

共 3 条

[1] Anti-hypertrophy effect of atorvastatin on myocardium depends on AMPK activation-induced miR-143-3p suppression via Foxo1
Yu, Bo
Liu, Dongna
Zhang, Hongli
Xie, Di
Nie, Wei
Shi, Kaiyao
Yang, Ping
BIOMEDICINE & PHARMACOTHERAPY, 2018, 106 : 1390 - 1395
[2] Gypenoside A protects ischemia/reperfusion injuries by suppressing miR-143-3p level via the activation of AMPK/Foxo1 pathway
Chang, Liping
Shi, Rui
Wang, Xiujiang
Bao, Yang
BIOFACTORS, 2020, 46 (03) : 432 - 440
[3] Suppression of miR-143-3p contributes to the anti-fibrosis effect of atorvastatin on myocardial tissues via the modulation of Smad2 activity
Yu, Bo
Yu, Ming
Zhang, Hongli
Xie, Di
Nie, Wei
Shi, Kaiyao
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2020, 112

← 1 →